Novo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival ...Middle East

Fortune - News
Novo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival
Novo Nordisk faces opposition from local rival, Zealand Pharma. The pharma company has so far risen 63% in market value on the Copenhagen stock exchange this year compared with 40% for its larger peer.

Hence then, the article about novo nordisk became europe s most valuable company with the rise of wegovy and ozempic but it s facing stiff competition from a local pharma rival was published today ( ) and is available on Fortune ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News